Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma – PHARMA
Puma Biotechnology
PharmaBg
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019